Effects of Bisphosphonate on the Release of MMP-2 from Cultured Human Osteoblasts
Overview
Affiliations
Production of matrix metalloproteinases (MMPs) influences bone resorption. We investigated the role of bisphosphonates, potent inhibitors of bone resorption, on the production of MMP-2 from human osteoblasts. Bisphosphonates alone did not influence the amount of MMP-2 produced by human osteoblasts. However, in the presence of physiological concentrations of plasmin, bisphosphonates reduced the amount of MMP-2 in osteoblasts-conditioned media. Furthermore, bisphosphonates treatment induced degradation of MMP-2 in the presence of plasmin. Our results indicated that bisphosphonate, a divalent cation chelator, negatively regulated the longevity of MMP-2 in soluble phase plasmin-containing environment. These findings suggest that bisphosphonates inhibit bone resorption by abrogating MMP-2 protection induced by plasmin-mediated degradation.
Potential options for managing LOX+ ER- breast cancer patients.
Han Y, Lian S, Cui X, Meng K, Gyorffy B, Jin T Oncotarget. 2016; 7(22):32893-901.
PMID: 27147578 PMC: 5078060. DOI: 10.18632/oncotarget.9073.
Risedronate inhibits human osteosarcoma cell invasion.
Xin Z, Kim Y, Jung S J Exp Clin Cancer Res. 2009; 28:105.
PMID: 19624845 PMC: 2729740. DOI: 10.1186/1756-9966-28-105.
Luo X, Guo L, Shan P, Xie H, Wu X, Zhang H Osteoporos Int. 2005; 17(4):521-6.
PMID: 16365830 DOI: 10.1007/s00198-005-0017-6.